Melanoma Coverage from Every Angle

Piotr Rutkowski, MD, PhD, on Melanoma: Neoadjuvant and Adjuvant Strategies

Posted: Thursday, October 25, 2018

Piotr Rutkowski, MD, PhD, of Maria Sklodowska-Curie Institute of Oncology, discusses recent treatment advances in metastatic melanoma and high-risk locoregional disease, including immunotherapy with checkpoint inhibitors and targeted therapy with BRAF plus MEK inhibitors.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.